Intensity Therapeutics, Common Stock Current Liabilities
| INTS Stock | 0.41 0.03 7.89% |
Fundamental analysis of Intensity Therapeutics, allows traders to better anticipate movements in Intensity Therapeutics,'s stock price by examining its financial health and performance throughout various phases of its business cycle.
Total Current Liabilities is likely to gain to about 3.4 M in 2025, whereas Non Current Liabilities Total is likely to drop slightly above 104.5 K in 2025. Intensity | Current Liabilities | Build AI portfolio with Intensity Stock |
Intensity Therapeutics, Common Company Current Liabilities Analysis
Intensity Therapeutics,'s Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Intensity Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Intensity Therapeutics, is extremely important. It helps to project a fair market value of Intensity Stock properly, considering its historical fundamentals such as Current Liabilities. Since Intensity Therapeutics,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Intensity Therapeutics,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Intensity Therapeutics,'s interrelated accounts and indicators.
Click cells to compare fundamentals
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Intensity Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Intensity Therapeutics, Common has a Current Liabilities of 0.0. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Intensity Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Intensity Therapeutics,'s direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Intensity Therapeutics, could also be used in its relative valuation, which is a method of valuing Intensity Therapeutics, by comparing valuation metrics of similar companies.Intensity Therapeutics, is currently under evaluation in current liabilities category among its peers.
Intensity Therapeutics, Current Valuation Drivers
We derive many important indicators used in calculating different scores of Intensity Therapeutics, from analyzing Intensity Therapeutics,'s financial statements. These drivers represent accounts that assess Intensity Therapeutics,'s ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Intensity Therapeutics,'s important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Enterprise Value | 69.3M | 75.9M | 81.3M | 65.4M | 22.0M | 20.9M |
Intensity Fundamentals
| Return On Equity | -2.35 | ||||
| Return On Asset | -1.02 | ||||
| Current Valuation | 15.16 M | ||||
| Shares Outstanding | 60.06 M | ||||
| Shares Owned By Insiders | 10.38 % | ||||
| Shares Owned By Institutions | 7.01 % | ||||
| Number Of Shares Shorted | 2.95 M | ||||
| Price To Book | 3.06 X | ||||
| EBITDA | (16.27 M) | ||||
| Net Income | (16.27 M) | ||||
| Total Debt | 138 K | ||||
| Book Value Per Share | 0.15 X | ||||
| Cash Flow From Operations | (15.22 M) | ||||
| Short Ratio | 0.88 X | ||||
| Earnings Per Share | (0.55) X | ||||
| Target Price | 2.92 | ||||
| Beta | 4.24 | ||||
| Market Capitalization | 22.56 M | ||||
| Total Asset | 4.78 M | ||||
| Retained Earnings | (66.78 M) | ||||
| Working Capital | 1.61 M | ||||
| Net Asset | 4.78 M |
About Intensity Therapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Intensity Therapeutics, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intensity Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intensity Therapeutics, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Intensity Stock Analysis
When running Intensity Therapeutics,'s price analysis, check to measure Intensity Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intensity Therapeutics, is operating at the current time. Most of Intensity Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Intensity Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intensity Therapeutics,'s price. Additionally, you may evaluate how the addition of Intensity Therapeutics, to your portfolios can decrease your overall portfolio volatility.